☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
France | Not | |
State or other jurisdiction of incorporation or organization | (I.R.S. Employer Identification No.) | |
177-181 avenue Pierre Brossolette92120 Montrouge France | ||
(Address of principal executive offices) | (Zip Code) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
American Depositary Shares, each representing one-half of one ordinary share, nominal value €0.10 per share | DBVT | The Nasdaq Stock Market LLC | ||
Ordinary shares, nominal value €0.10 per share* | n/a | The Nasdaq Stock Market LLC |
* | Not for trading, but only in connection with the registration of the American Depositary Shares. |
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
Table of contents
Unless the context otherwise requires, we use the terms “DBV”, “DBV Technologies,” the “Company,” “we,” “us” and “our” in this Quarterly Report on
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS.
This Quarterly Report contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended or Securities Act,(the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended or Exchange Act.(the “Exchange Act”). These statements may be identified by such forward-looking terminology as “may,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue” or variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Any forward-looking statement involves known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statement. Forward-looking statements include statements, other than statements of historical fact, about, among other things:
• | our expectations regarding the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated re-submission of a Biologics License Application, or a BLA, for ViaskinTM Peanut to the U.S. Food and Drug Administration, or the FDA; |
the timing or likelihood of regulatory filings and approvals, including with respect to our anticipated
• | the initiation, timing, progress and results of ourpre-clinical studies and clinical trials, and our research and development programs; |
the sufficiency of existing capital resources;
our business model and our other strategic plans for our business, product candidates and technology;
our ability to manufacture clinical and commercial supplies of our product candidates and comply with regulatory requirements related to the manufacturing of our product candidates;
our ability to build our own sales and marketing capabilities, or seek collaborative partners, to commercialize Viaskin Peanut and/or our other product candidates, if approved;
the commercialization of our product candidates, if approved;
our expectations regarding the potential market size and the size of the patient populations for Viaskin Peanut and/or our other product candidates, if approved, and our ability to serve such markets;
the pricing and reimbursement of our product candidates, if approved;
the rate and degree of market acceptance of Viaskin Peanut and/or our other product candidates, if approved, by physicians, patients, third-party payors and others in the medical community;
our ability to advance product candidates into, and successfully complete, clinical trials;
the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;
estimates of our expenses, future revenues, capital requirements and our needs for additional financing;
the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements;
our ability to maintain and establish collaborations or obtain additional grant funding;
our financial performance;
developments relating to our competitors and our industry, including competing therapies;
• | the impact of the COVID-19 pandemic and its effects on our operations, research and development, clinical trials and ability to obtain financing and potential disruption in the operations and business of third-party manufacturers, contract research organizations, or CROs, other service providers and collaborators with whom we conduct business; and |
other risks and uncertainties, including those listed under the caption “Risk Factors.”
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report, these statements are based on our estimates or projections of the future that are subject to known and unknown risks and uncertainties and other important factors that may cause our actual results, level of activity, performance, experience or achievements to differ materially from those expressed or implied by any forward-looking statement. These risks, uncertainties and other factors are described in greater detail under the caption “Risk Factors” in Part I. Item 1A of our Annual Report on Form
1
In addition, any forward-looking statement in this Quarterly Report, including statements that “we believe” and similar statements, reflect our beliefs and opinions on the relevant subject and represents our views only as of the date of this Quarterly Report and should not be relied upon as representing our views as of any subsequent date. These statements are based upon information available to us as of the date of this Quarterly Report and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. We anticipate that subsequent events and developments may cause our views to change. Although we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, except as required by applicable law. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.
2
June 30, | December 31, | June 30, | December 31, | |||||||||||||||||||
Note | 2022 | 2021 | Note | 2023 | 2022 | |||||||||||||||||
Assets | ||||||||||||||||||||||
Current assets: | ||||||||||||||||||||||
Cash and cash equivalents | 3 | $ | 247,971 | $ | 77,301 | 3 | $ | 173,961 | $ | 209,194 | ||||||||||||
Other current assets | 4 | 11,981 | 37,085 | 4 | 21,578 | 13,880 | ||||||||||||||||
Total current assets | 259,953 | 114,386 | 195,539 | 223,074 | ||||||||||||||||||
Property, plant, and equipment, net | 15,677 | 18,146 | 14,135 | 15,096 | ||||||||||||||||||
Right-of-use | 5 | 3,146 | 7,336 | 5 | 1,832 | 2,513 | ||||||||||||||||
Intangible assets | 14 | 22 | 68 | 10 | ||||||||||||||||||
Other non-current assets | 6,189 | 6,833 | 5,944 | 5,824 | ||||||||||||||||||
Total non-current assets | 25,025 | 32,338 | 21,979 | 23,444 | ||||||||||||||||||
Total Assets | $ | 284,978 | $ | 146,723 | $ | 217,518 | $ | 246,518 | ||||||||||||||
Liabilities and shareholders’ equity | ||||||||||||||||||||||
Current liabilities: | ||||||||||||||||||||||
Trade payables | 6 | $ | 16,341 | $ | 11,429 | 6 | $ | 19,094 | $ | 14,473 | ||||||||||||
Short-term operating leases | 5 | 1,968 | 3,003 | 5 | 1,944 | 1,894 | ||||||||||||||||
Short-term financial debt | 156 | 510 | ||||||||||||||||||||
Current contingencies | 9 | 3,189 | 4,095 | 9 | 5,076 | 3,944 | ||||||||||||||||
Other current liabilities | 6 | 8,778 | 12,361 | 6 | 7,258 | 9,210 | ||||||||||||||||
Total current liabilities | 30,431 | 31,397 | 33,373 | 29,521 | ||||||||||||||||||
Long-term operating leases | 5 | 1,945 | 7,147 | 5 | 187 | 1,127 | ||||||||||||||||
Non-current contingencies | 9 | 6,421 | 6,758 | 9 | 15,731 | 16,680 | ||||||||||||||||
Other non-current liabilities | 6 | 1,764 | 2,147 | 6 | 3,987 | 4,735 | ||||||||||||||||
Total non-current liabilities | 10,130 | 16,052 | 19,905 | 22,543 | ||||||||||||||||||
Total Liabilities | $ | 40,562 | $ | 47,449 | $ | 53,277 | $ | 52,064 | ||||||||||||||
Shareholders’ equity: | ||||||||||||||||||||||
Ordinary shares, €0.10 par value; 94,022,679 and 55,095,762 shares authorized, and issued as at June 30, 2022 and December 31, 2021, respectively | $ | 10,708 | $ | 6,538 | ||||||||||||||||||
Ordinary shares, €0.10 par value; 96,250,954 and 94,137,145 shares authorized, and issued as of June 30, 2023 and December 31, 2022, respectively | $ | 10,952 | $ | 10,720 | ||||||||||||||||||
Additional paid-in capital | 456,447 | 358,115 | 375,759 | 458,221 | ||||||||||||||||||
Treasury stock, 106,287 and 153,631 ordinary shares as of June 30, 2022 and December 31, 2021, respectively, at cost | (953 | ) | (1,232 | ) | ||||||||||||||||||
Treasury stock, 149,972 and 149,793 ordinary shares as of June 30, 2023 and December 31, 2022, respectively, at cost | (1,082 | ) | (1,109 | ) | ||||||||||||||||||
Accumulated deficit | (203,050 | ) | (258,528 | ) | (210,940 | ) | (259,578 | ) | ||||||||||||||
Accumulated other comprehensive income | 743 | 519 | 687 | 781 | ||||||||||||||||||
Accumulated currency translation effect | (19,480 | ) | (6,137 | ) | (11,136 | ) | (14,581 | ) | ||||||||||||||
Total Shareholders’ equity | 7 | $ | 244,416 | $ | 99,274 | 7 | $ | 164,240 | $ | 194,453 | ||||||||||||
Total Liabilities and Shareholders’ equity | $ | 284,978 | $ | 146,723 | $ | 217,518 | $ | 246,518 | ||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||||||||||||||||
Note | 2022 | 2021 | 2022 | 2021 | Note | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||||||||
Operating income | 10 | $ | 1,529 | $ | (1,488 | ) | $ | 4,074 | $ | 1,453 | 10 | $ | 2,288 | $ | 1,529 | $ | 4,482 | $ | 4,074 | |||||||||||||||||||
Operating expenses | ||||||||||||||||||||||||||||||||||||||
Research and development expenses | (18,611 | ) | (20,179 | ) | (30,834 | ) | (42,343 | ) | (17,616 | ) | (18,611 | ) | (33,653 | ) | (30,834 | ) | ||||||||||||||||||||||
Sales and marketing expenses | (1,037 | ) | (1,198 | ) | (1,500 | ) | (1,927 | ) | (516 | ) | (1,037 | ) | (950 | ) | (1,500 | ) | ||||||||||||||||||||||
General and administrative expenses | (5,704 | ) | (8,269 | ) | (12,334 | ) | (17,951 | ) | (9,231 | ) | (5,704 | ) | (16,120 | ) | (12,334 | ) | ||||||||||||||||||||||
Total Operating expenses | (25,352 | ) | (29,646 | ) | (44,669 | ) | (62,221 | ) | (27,364 | ) | (25,352 | ) | (50,723 | ) | (44,669 | ) | ||||||||||||||||||||||
Loss from operations | (23,823 | ) | (31,134 | ) | (40,595 | ) | (60,768 | ) | (25,076 | ) | (23,823 | ) | (46,242 | ) | (40,595 | ) | ||||||||||||||||||||||
Financial income | 784 | 46 | 936 | 261 | ||||||||||||||||||||||||||||||||||
Financial income (expenses) | 846 | 784 | 1,450 | 936 | ||||||||||||||||||||||||||||||||||
Loss before taxes | (23,039 | ) | (31,088 | ) | (39,659 | ) | (60,507 | ) | (24,230 | ) | (23,039 | ) | (44,791 | ) | (39,659 | ) | ||||||||||||||||||||||
Income tax | — | 434 | (87 | ) | 404 | (13 | ) | — | (13 | ) | (87 | ) | ||||||||||||||||||||||||||
Net loss | $ | (23,039 | ) | $ | (30,654 | ) | $ | (39,746 | ) | $ | (60,103 | ) | $ | (24,243 | ) | $ | (23,039 | ) | $ | (44,804 | ) | $ | (39,746 | ) | ||||||||||||||
Foreign currency translation differences, net of taxes | (11,394 | ) | 2,788 | (13,327 | ) | (5,956 | ) | (221 | ) | (11,394 | ) | 3,445 | (13,327 | ) | ||||||||||||||||||||||||
Actuarial gains (losses) on employee benefits, net of taxes | 200 | 48 | 224 | (38 | ) | (10 | ) | 200 | (92 | ) | 224 | |||||||||||||||||||||||||||
Total comprehensive loss | $ | (34,234 | ) | $ | (27,818 | ) | $ | (52,849 | ) | $ | (66,097 | ) | $ | (24,475 | ) | $ | (34,234 | ) | $ | (41,452 | ) | $ | (52,849 | ) | ||||||||||||||
Basic/diluted net loss per share attributable to shareholders | 14 | $ | (0.35 | ) | $ | (0.56 | ) | $ | (0.66 | ) | $ | (1.09 | ) | 14 | $ | (0.26 | ) | $ | (0.35 | ) | $ | (0.48 | ) | $ | (0.66 | ) | ||||||||||||
Weighted average shares outstanding used in computing per share amounts: | 66,047,949 | 54,904,764 | 60,490,075 | 54,892,794 | 94,324,889 | 66,047,949 | 94,150,141 | 60,490,075 |
Six Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||||
Notes | 2022 | 2021 | Notes | 2023 | 2022 | |||||||||||||||||
Net loss for the period | $ | (39,746 | ) | $ | (60,103 | ) | $ | (44,804 | ) | $ | (39,746 | ) | ||||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||||||||||
Adjustments to reconcile net loss to net cash flow provided by (used in) operating activities: | ||||||||||||||||||||||
Depreciation, amortization and accrued contingencies | 1,249 | 8,619 | 369 | 1,249 | ||||||||||||||||||
Retirement pension obligations | 14 | 57 | 11 | 14 | ||||||||||||||||||
Expenses related to share-based payments | 8 | 2,441 | 2,527 | 8 | 3,446 | 2,441 | ||||||||||||||||
Other elements | (3 | ) | (843 | ) | 23 | (3 | ) | |||||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||||||||||
Decrease (increase) in trade receivables | — | 2,175 | ||||||||||||||||||||
Decrease (increase) in other current assets | 23,436 | (8,393 | ) | (6,481 | ) | 23,436 | ||||||||||||||||
(Decrease) increase in trade payables | 5,894 | (3,165 | ) | 3,419 | 5,894 | |||||||||||||||||
(Decrease) increase in other current and non-current liabilities | (3,040 | ) | (6,608 | ) | (2,913 | ) | (3,040 | ) | ||||||||||||||
Change in operating lease liabilities and right of use assets | (1,979 | ) | (769 | ) | 535 | (1,979 | ) | |||||||||||||||
Net cash flow used in operating activities | (11,733 | ) | (66,503 | ) | ||||||||||||||||||
Net cash flow provided by (used in) operating activities | (46,394 | ) | (11,733 | ) | ||||||||||||||||||
Cash flows used in investing activities: | ||||||||||||||||||||||
Cash flows provided by (used in) investing activities: | ||||||||||||||||||||||
Acquisitions of property, plant, and equipment, net from proceeds | (369 | ) | (13 | ) | (275 | ) | (369 | ) | ||||||||||||||
Proceeds from property, plant, and equipment dispositions | 3 | — | — | 3 | ||||||||||||||||||
Acquisitions of non-current financial assets | (279 | ) | — | (27 | ) | (279 | ) | |||||||||||||||
Proceeds from non-current financial assets | 426 | — | ||||||||||||||||||||
Proceeds from non-current financial assets dispositions | 4 | 426 | ||||||||||||||||||||
Net cash flows used in investing activities | (218 | ) | (13 | ) | ||||||||||||||||||
Net cash flows provided by (used in) investing activities | (299 | ) | (218 | ) | ||||||||||||||||||
Cash flows provided by financing activities: | ||||||||||||||||||||||
Cash flows provided by (used in) financing activities: | ||||||||||||||||||||||
Decrease in conditional advances | (328 | ) | (345 | ) | — | (328 | ) | |||||||||||||||
Treasury shares | 279 | 638 | 27 | 279 | ||||||||||||||||||
Capital increases, net of transaction costs | 195,270 | 794 | 7,766 | 195,270 | ||||||||||||||||||
Other cash flows related to financing activities | — | (17 | ) | — | — | |||||||||||||||||
Net cash flows provided by financing activities | 195,221 | 1,071 | ||||||||||||||||||||
Net cash flows provided by (used in) financing activities | 7,793 | 195,221 | ||||||||||||||||||||
Effect of exchange rate changes on cash and cash equivalents | (12,600 | ) | (5,423 | ) | 3,668 | (12,600 | ) | |||||||||||||||
Net increase (decrease) in cash and cash equivalents | 170,670 | (70,868 | ) | (35,232 | ) | 170,670 | ||||||||||||||||
Net Cash and cash equivalents at the beginning of the period | 77,301 | 196,352 | 209,194 | 77,301 | ||||||||||||||||||
Net cash and cash equivalents at the end of the period | 3 | $ | 247,971 | $ | 125,484 | 3 | $ | 173,961 | $ | 247,971 | ||||||||||||
Ordinary shares | ||||||||||||||||||||||||||||||||
Number of Shares | Amount | Additional paid-in capital | Treasury stock | Accumulated deficit | Accumulated other comprehensive income (loss) | Accumulated currency translation effect | Total Shareholders’ Equity | |||||||||||||||||||||||||
Balance at January 1, 2021 | 54,929,187 | $ | 6,518 | $ | 1,152,042 | $ | (1,169 | ) | $ | (958,543 | ) | $ | 484 | $ | 6,158 | $ | 205,491 | |||||||||||||||
Net (loss) | — | — | — | — | (29,449 | ) | — | — | (29,449 | ) | ||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | (85 | ) | (8,744 | ) | (8,829 | ) | |||||||||||||||||||||
Issuance of ordinary shares | 7,500 | 1 | 42 | — | — | — | — | 42 | ||||||||||||||||||||||||
Treasury shares | — | — | — | 488 | — | — | — | 488 | ||||||||||||||||||||||||
Share-based payments | — | — | 1,433 | — | — | — | — | 1,433 | ||||||||||||||||||||||||
Balance at March 31, 2021 | 54,936,687 | $ | 6,519 | $ | 1,153,516 | $ | (681 | ) | $ | (987,992 | ) | $ | 399 | $ | (2,586 | ) | $ | 169,176 | ||||||||||||||
Net (loss) | — | — | — | — | (30,654 | ) | — | — | (30,654 | ) | ||||||||||||||||||||||
Other comprehensive income | — | — | — | — | — | 48 | 2,788 | 2,836 | ||||||||||||||||||||||||
Issuance of ordinary shares | 75,000 | 9 | 464 | — | — | — | — | 473 | ||||||||||||||||||||||||
Insuance of warrants | 279 | 279 | ||||||||||||||||||||||||||||||
Treasury shares | — | — | (185 | ) | — | — | — | (185 | ) | |||||||||||||||||||||||
Share-based payments | — | — | 1,094 | — | — | — | 1,094 | |||||||||||||||||||||||||
Allocation of accumulated net losses | — | — | (797,823 | ) | — | 797,823 | — | — | — | |||||||||||||||||||||||
Balance at June 30, 2021 | 55,011,687 | $ | 6,529 | $ | 357,530 | $ | (866 | ) | $ | (220,823 | ) | $ | 446 | $ | 203 | $ | 143,019 |
Ordinary shares | ||||||||||||||||||||||||||||||||
Number of Shares | Amount | Additional paid-in capital | Treasury stock | Accumulated deficit | Accumulated other comprehensive income (loss) | Accumulated currency translation effect | Total Shareholders’ Equity | |||||||||||||||||||||||||
Balance at January 1, 2022 | 55,095,762 | $ | 6,538 | $ | 358,115 | $ | (1,232 | ) | $ | (258,528 | ) | $ | 519 | $ | (6,137 | ) | $ | 99,274 | ||||||||||||||
Net (loss) | — | — | — | — | (16,706 | ) | — | — | (16,706 | ) | ||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | 24 | (1,933 | ) | (1,909 | ) | ||||||||||||||||||||||
Issuance of ordinary shares | 775 | 1 | — | — | — | — | — | 1 | ||||||||||||||||||||||||
Treasury shares | — | — | — | 40 | — | — | — | 40 | ||||||||||||||||||||||||
Share-based payments | — | — | 1,363 | — | — | — | — | 1,363 | ||||||||||||||||||||||||
Other change in equity | — | — | — | — | 15 | — | (15 | ) | — | |||||||||||||||||||||||
Balance at March 31, 2022 | 55,096,537 | $ | 6,539 | $ | 359,478 | $ | (1,193 | ) | $ | (275,219 | ) | $ | 543 | $ | (8,086 | ) | $ | 82,062 | ||||||||||||||
Net (loss) | — | — | — | — | (23,039 | ) | — | — | (23,039 | ) | ||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | 200 | (11,394 | ) | (11,194 | ) | ||||||||||||||||||||||
Issuance of ordinary shares | 38,926,142 | 4,170 | 103,007 | — | — | — | — | 107,176 | ||||||||||||||||||||||||
Issuance of warrants | — | — | 88,094 | — | — | — | — | 88,094 | ||||||||||||||||||||||||
Treasury shares | — | — | — | 240 | — | — | — | 240 | ||||||||||||||||||||||||
Share-based payments | — | — | 1,078 | — | — | — | — | 1,078 | ||||||||||||||||||||||||
Allocation of accumulated net losses | — | — | (95,209 | ) | — | 95,209 | — | — | — | |||||||||||||||||||||||
Balance at June 30, 2022 | 94,022,679 | $ | 10,708 | $ | 456,447 | $ | (953 | ) | $ | (203,050 | ) | $ | 743 | $ | (19,480 | ) | $ | 244,416 |
Ordinary shares | Ordinary shares | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number of Shares | Amount | Additional paid-in capital | Treasury stock | Accumulated deficit | Accumulated other comprehensive income (loss) | Accumulated currency translation effect | Total Shareholders’ Equity | Number of Shares | Amount | Additional paid-in capital | Treasury stock | Accumulated deficit | Accumulated other comprehensive income (loss) | Accumulated currency translation effect | Total Shareholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
Balance at January 1, 2022 | 55,095,762 | $ | 6,538 | $ | 358,115 | $ | (1,232 | ) | $ | (258,528 | ) | $ | 519 | $ | (6,137 | ) | $ | 99,274 | ||||||||||||||||||||||||||||||||||||||||||||||
Balance at January 1, 2023 | 94,137,145 | $ | 10,720 | $ | 458,221 | $ | (1,109 | ) | $ | (259,578 | ) | $ | 781 | $ | (14,581 | ) | $ | 194,453 | ||||||||||||||||||||||||||||||||||||||||||||||
Net (loss) | — | — | — | — | (16,706 | ) | — | — | (16,706 | ) | — | — | — | — | (20,561 | ) | — | — | (20,561 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | 24 | (1,933 | ) | (1,909 | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insuance of ordinary shares | 775 | 1 | — | — | — | — | — | 1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | (82 | ) | 3,666 | 3,584 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of ordinary shares | 10,174 | 1 | (1 | ) | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury shares | — | — | — | 40 | — | — | — | 40 | — | — | — | (14 | ) | — | — | — | (14 | ) | ||||||||||||||||||||||||||||||||||||||||||||||
Share-based payments | — | — | 1,363 | — | — | — | — | 1,363 | — | — | 1,632 | — | — | — | — | 1,632 | ||||||||||||||||||||||||||||||||||||||||||||||||
Other changes | — | — | — | — | 15 | (15 | ) | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2022 | 55,096,537 | $ | 6,539 | $ | 359,478 | $ | (1,193 | ) | $ | (275,219 | ) | $ | 543 | $ | (8,086 | ) | $ | 82,062 | ||||||||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2023 | 94,147,319 | $ | 10,721 | $ | 459,852 | $ | (1,123 | ) | $ | (280,138 | ) | $ | 698 | $ | (10,915 | ) | $ | 179,094 | ||||||||||||||||||||||||||||||||||||||||||||||
Net (loss) | — | — | — | — | (23,039 | ) | — | — | (23,039 | ) | — | — | — | — | (24,243 | ) | — | — | (24,243 | ) | ||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | 200 | (11,394 | ) | (11,194 | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | — | — | — | — | — | (10 | ) | (221 | ) | (232 | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of ordinary shares | 38,926,142 | 4,170 | 103,007 | — | — | — | — | 107,176 | 2,103,635 | 231 | 7,535 | — | — | — | — | 7,766 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of warrants | — | — | 88,094 | — | — | — | — | 88,094 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Treasury shares | — | — | — | 240 | — | — | — | 240 | — | — | — | 42 | — | — | — | 42 | ||||||||||||||||||||||||||||||||||||||||||||||||
Share-based payments | — | — | 1,078 | — | — | — | — | 1,078 | — | — | 1,814 | — | — | — | — | 1,814 | ||||||||||||||||||||||||||||||||||||||||||||||||
Allocation of accumulated net losses | — | — | (95,209 | ) | — | 95,209 | — | — | — | — | — | (93,441 | ) | — | 93,441 | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2022 | 94,022,679 | $ | 10,708 | $ | 456,447 | $ | (953 | ) | $ | (203,050 | ) | $ | 743 | $ | (19,480 | ) | $ | 244,416 | ||||||||||||||||||||||||||||||||||||||||||||||
Balance at June 30, 2023 | 96,250,954 | $ | 10,952 | $ | 375,759 | $ | (1,082 | ) | $ | (210,940 | ) | $ | 687 | $ | (11,136 | ) | $ | 164,240 |
1. | Identify a modified Viaskin patch (which the Company calls |
2. | Generate the 6-month safety and adhesion clinical data FDA requested via STAMP, which the Company expected to be the longest component of the mVP clinical plan. The Company prioritized the STAMP protocol submission so the Company could begin the study as soon as possible. |
3. | Demonstrate the equivalence in allergen uptake between the current and modified patches in the intended patient population via EQUAL. The complexity of EQUAL hinged on the lack of established clinical and regulatory criteria to characterize allergen uptake via an epicutaneous patch. To support those exchanges, the Company outlined its proposed approach to demonstrate allergen uptake equivalence between the two patches, and allotted time to generate informative data through two additional |
a. | PREQUAL, a Phase . The data collection phase of the trial is complete, and the data analysis phase is ongoing. |
b. | ‘EQUAL in adults’—a second Phase I study with adult healthy volunteers to compare the allergen uptake of cVP and |
June 30, | December 31, | June 30, | December 31, | |||||||||||||
2022 | 2021 | 2023 | 2022 | |||||||||||||
Cash | 226,674 | 31,427 | 24,111 | 30,104 | ||||||||||||
Cash equivalents | 21,298 | 45,874 | 149,850 | 179,090 | ||||||||||||
Total cash and cash equivalents as reported in the statements of financial position | 247,971 | 77,301 | 173,961 | 209,194 | ||||||||||||
Bank overdrafts | — | — | ||||||||||||||
Total cash and cash equivalents as reported in the statements of cash flows | 173,961 | 209,194 |
June 30, | December 31, | |||||||
2022 | 2021 | |||||||
Research tax credit | 2,908 | 28,092 | ||||||
Other tax claims | 4,339 | 3,561 | ||||||
Prepaid expenses | 3,773 | 4,149 | ||||||
Other receivables | 961 | 1,283 | ||||||
Total | 11,981 | 37,085 | ||||||
June 30, 2023 | December 31, 2022 | |||||||
Research tax credit | 9,662 | 5,792 | ||||||
Other tax claims | 5,851 | 3,903 | ||||||
Prepaid expenses | 4,494 | 2,680 | ||||||
Other receivables | 1,571 | 1,504 | ||||||
Total | 21,578 | 13,880 | ||||||
Amount in thousands of US Dollars | ||||
Opening research tax credit receivable as of January 1, | ||||
5,792 | ||||
+ Operating revenue | 3,741 | |||
- Payment received | — | |||
- Adjustment and currency translation effect | 130 | |||
Closing research tax credit receivable as of June 30, 2023 | ||||
Of which - | — | |||
Of which - Current portion |
June 30, 2022 | December 31, 2021 | June 30, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||||
Real estate | Other assets | Total | Real estate | Other assets | Total | Real estate | Other assets | Total | Real estate | Other assets | Total | |||||||||||||||||||||||||||||||||||||
Current portion | 2,104 | 50 | 2,154 | 3,361 | 77 | 3,438 | 1,886 | 74 | 1,961 | 1,972 | 79 | 2,051 | ||||||||||||||||||||||||||||||||||||
Year 2 | 1,843 | 19 | 1,862 | 3,124 | 23 | 3,147 | 291 | 43 | 334 | 1,168 | 74 | 1,243 | ||||||||||||||||||||||||||||||||||||
Year 3 | 284 | 11 | 295 | 2,299 | 18 | 2,317 | — | — | — | 65 | 6 | 71 | ||||||||||||||||||||||||||||||||||||
Year 4 | — | — | — | 771 | 1 | 773 | ||||||||||||||||||||||||||||||||||||||||||
Year 5 | — | — | — | 790 | — | 790 | ||||||||||||||||||||||||||||||||||||||||||
Thereafter | — | — | — | 1,220 | — | 1,220 | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||
Total minimum lease payments | 4,231 | 80 | 4,311 | 11,565 | 119 | 11,684 | 2,177 | 118 | 2,295 | 3,204 | 160 | 3,364 | ||||||||||||||||||||||||||||||||||||
Less: Effects of discounting | (363 | ) | (6 | ) | (370 | ) | (1,526 | ) | (8 | ) | (1,534 | ) | (153 | ) | (10 | ) | (163 | ) | (325 | ) | (17 | ) | (343 | ) | ||||||||||||||||||||||||
Present value of operating lease | 3,868 | 73 | 3,941 | 10,039 | 111 | 10,150 | 2,024 | 107 | 2,131 | 2,879 | 143 | 3,021 | ||||||||||||||||||||||||||||||||||||
Less: current portion | (1,922 | ) | (46 | ) | (1,968 | ) | (2,929 | ) | (74 | ) | (3,003 | ) | (1,873 | ) | (72 | ) | (1,944 | ) | (1,823 | ) | (71 | ) | (1,894 | ) | ||||||||||||||||||||||||
Long-term operating lease | 1,946 | 27 | 1,973 | 7,110 | 37 | 7,147 | 151 | 36 | 187 | 1,055 | 72 | 1,127 | ||||||||||||||||||||||||||||||||||||
Weighted average remaining lease term (years) | 1.79 | — | 4.14 | 2.01 | 0.95 | — | 1.40 | — | ||||||||||||||||||||||||||||||||||||||||
Weighted average discount rate | 3.14 | % | 1.29 | % | 4.84 | % | 3.32 | % | 2.90 | % | 2.50 | % | 3.00 | % | 2.45 | % |
June 30, | |||||||
2022 | 2021 | ||||||
Operating lease expense | 950 | 1,698 | |||||
Net termination impact | (1,657 | ) | — |
June 30, | ||||||||
2023 | 2022 | |||||||
Operating lease expense / (income) | 1,543 | 950 | ||||||
Net termination impact | (920 | ) | (1,657 | ) |
June 30, | June 30, | |||||||||||||
2022 | 2021 | 2023 | 2022 | |||||||||||
Cash paid for amounts included in the measurement of lease liabilities | — | — | ||||||||||||
Operating cash flows from operating leases | 1,079 | 2,077 | ||||||||||||
Operating cash outflows related to operating leases | 963 | 1,079 |
June 30, | December 31, | |||||||||||||||||||||||
2022 | 2021 | |||||||||||||||||||||||
Other current liabilities | Other non-current liabilities | Total | Other current liabilities | Other non-current liabilities | Total | |||||||||||||||||||
Employee related liabilities | 4,135 | 77 | 4,212 | 6,708 | 247 | 6,954 | ||||||||||||||||||
Deferred income | 3,012 | 1,687 | 4,700 | 4,146 | 1,900 | 6,046 | ||||||||||||||||||
Tax liabilities | 400 | — | 400 | 182 | — | 182 | ||||||||||||||||||
Other debts | 1,231 | — | 1,231 | 1,325 | — | 1,325 | ||||||||||||||||||
Total | 8,778 | 1,764 | 10,542 | 12,361 | 2,147 | 14,508 | ||||||||||||||||||
June 30, | December 31, | |||||||||||||||||||||||
2023 | 2022 | |||||||||||||||||||||||
Other current liabilities | Other non-current liabilities | Total | Other current liabilities | Other non-current liabilities | Total | |||||||||||||||||||
Employee related liabilities | 4,374 | — | 4,374 | 5,872 | 45 | 5,917 | ||||||||||||||||||
Deferred income | 2,264 | 3,987 | 6,251 | 2,137 | 4,690 | 6,828 | ||||||||||||||||||
Tax liabilities | 187 | — | 187 | 69 | — | 69 | ||||||||||||||||||
Other debts | 433 | — | 433 | 1,131 | — | 1,131 | ||||||||||||||||||
Total | 7,258 | 3,987 | 11,245 | 9,210 | 4,735 | 13,945 | ||||||||||||||||||
warrants | ||||
Number of outstanding | ||||||||||||
BSA | SO | RSUs | ||||||||||
Balance as of December 31, 2022 | 251,693 | 5,306,569 | 1,589,081 | |||||||||
Granted during the period | — | 59,200 | 35,800 | |||||||||
Forfeited during the period | — | (75,200 | ) | (54,444 | ) | |||||||
Exercised/released during the period | — | — | (61,359 | ) | ||||||||
Expired during the period | — | — | — | |||||||||
Balance as of June 30, 2023 | 251,693 | 5,290,569 | 1,509,078 | |||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||||||
Research & development | SO | (465 | ) | (290 | ) | (894 | ) | (665 | ) | |||||||||||
RSU | (271 | ) | (185 | ) | (529 | ) | (393 | ) | ||||||||||||
Sales & marketing | SO | (27 | ) | (38 | ) | (54 | ) | (33 | ) | |||||||||||
RSU | (8 | ) | (17 | ) | (17 | ) | (16 | ) | ||||||||||||
General & administrative | SO | (925 | ) | (478 | ) | (1,722 | ) | (1,176 | ) | |||||||||||
RSU | (118 | ) | (70 | ) | (231 | ) | (157 | ) | ||||||||||||
Total share-based compensation (expense) | (1,814 | ) | (1,078 | ) | (3,446 | ) | (2,441 | ) | ||||||||||||
June 30, | December 31, | |||||||
2023 | 2022 | |||||||
Current contingencies | 5,076 | 3,944 | ||||||
Non-current contingencies | 15,731 | 16,680 | ||||||
Total contingencies | 20,807 | 20,625 | ||||||
Pension retirement obligations | Collaboration agreement - Loss at completion | Other contingencies | Total | |||||||||||||
At January 1, 2023 | 790 | 19,835 | — | 20,625 | ||||||||||||
Increases in liabilities | 11 | — | 780 | 791 | ||||||||||||
Used liabilities | — | — | — | — | ||||||||||||
Reversals of unused liabilities | — | (1,083 | ) | — | (1,083 | ) | ||||||||||
Net interest related to employee benefits, and unwinding of discount | — | — | — | — | ||||||||||||
Actuarial gains and losses on defined-benefit plans | 93 | — | — | 93 | ||||||||||||
Currency translation effect | 15 | 366 | — | 381 | ||||||||||||
At June 30, 2023 | 909 | 19,118 | 780 | 20,807 | ||||||||||||
Of which Current | — | 4,296 | 780 | 5,076 | ||||||||||||
Of which Non-current | 909 | 14,822 | — | 15,731 |
Number of outstanding | ||||||||||||
BSA | SO | RSUs | ||||||||||
Balance as of December 31, 2021 | 256,693 | 3,631,210 | 1,240,520 | |||||||||
Granted during the period | — | 19,000 | 3,200 | |||||||||
Forfeited during the period | — | (205,728 | ) | (66,588 | ) | |||||||
Exercised/released during the period | — | (2,125 | ) | (31,910 | ) | |||||||
Expired during the period | — | — | — | |||||||||
Balance as of June 30, 2022 | 256,693 | 3,442,358 | 1,145,223 | |||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||||||
Research & development | SO | (290 | ) | (302 | ) | (665 | ) | (678 | ) | |||||||||||
RSU | (185 | ) | 115 | (393 | ) | (136 | ) | |||||||||||||
Sales & marketing | SO | (38 | ) | (63 | ) | (33 | ) | (112 | ) | |||||||||||
RSU | (17 | ) | (26 | ) | (16 | ) | (48 | ) | ||||||||||||
General & administrative | SO | (478 | ) | (709 | ) | (1,176 | ) | (1,353 | ) | |||||||||||
RSU | (70 | ) | (110 | ) | (157 | ) | (201 | ) | ||||||||||||
Total share-based compensation (expens e ) | (1,078 | ) | (1,094 | ) | (2,441 | ) | (2,527 | ) | ||||||||||||
June 30, | December 31, | |||||||
2022 | 2021 | |||||||
Current contingencies | 3,189 | 4,095 | ||||||
Non-current contingencies | 6,421 | 6,758 | ||||||
Total contingencies | 9,610 | 10,853 | ||||||
Pension retirement obligations | Collaboration agreement - Loss at completion | Other contingencies | Total | |||||||||||||
At January 1, 2022 | 1,008 | 9,800 | 45 | 10,853 | ||||||||||||
Increases in liabilities | 14 | — | — | 14 | ||||||||||||
Used liabilities | — | (108 | ) | (44 | ) | (152 | ) | |||||||||
Reversals of unused liabilities | — | — | — | — | ||||||||||||
Net interest related to employee benefits, and unwinding of discount | — | — | — | — | ||||||||||||
Actuarial gains and losses on defined-benefit plans | (224 | ) | — | — | (224 | ) | ||||||||||
Currency translation effect | (73 | ) | (807 | ) | (2 | ) | (882 | ) | ||||||||
At June 30, 2022 | 725 | 8,885 | — | 9,610 | ||||||||||||
Of which Current | — | 3,189 | — | 3,189 | ||||||||||||
Of which Non-current | 725 | 5,696 | — | 6,421 |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Research tax credit | 1,975 | 1,491 | 3,741 | 3,060 | ||||||||||||
Other operating income | 312 | 37 | 741 | 1,014 | ||||||||||||
Total | 2,288 | 1,529 | 4,482 | 4,074 | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Research tax credit | 1,491 | 1,870 | 3,060 | 3,677 | ||||||||||||
Other operating income | 37 | (3,358 | ) | 1,014 | (2,225 | ) | ||||||||||
Total | 1,529 | (1,488 | ) | 4,074 | 1,453 | |||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Research and Development expenses | 3,097 | 3,393 | 6,172 | 8,111 | ||||||||||||
Sales and Marketing expenses | 344 | 518 | 589 | 1,036 | ||||||||||||
General and Administrative expenses | 2,767 | 2,999 | 5,362 | 6,765 | ||||||||||||
Total personnel expenses | 6,208 | 6,910 | 12,123 | 15,912 | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Research and Development expenses | 4,014 | 3,097 | 8,020 | 6,172 | ||||||||||||
Sales and Marketing expenses | 208 | 344 | 373 | 589 | ||||||||||||
General and Administrative expenses | 2,858 | 2,767 | 5,958 | 5,362 | ||||||||||||
Total personnel expenses | 7,079 | 6,208 | 14,351 | 12,123 | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Wages and salaries | 3,509 | 4,382 | 7,497 | 8,836 | ||||||||||||
Social security contributions | 1,256 | 1,064 | 1,507 | 2,396 | ||||||||||||
Expenses for pension commitments | 211 | 293 | 509 | 695 | ||||||||||||
Employer contribution to bonus shares | 154 | 77 | 170 | 1,458 | ||||||||||||
Share-based payments | 1,078 | 1,094 | 2,441 | 2,527 | ||||||||||||
Total | 6,208 | 6,910 | 12,123 | 15,912 | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Wages and salaries | 4,078 | 3,509 | 8,516 | 7,497 | ||||||||||||
Social security contributions | 1,185 | 1,256 | 1,884 | 1,507 | ||||||||||||
Expenses for pension commitments | 246 | 211 | 504 | 509 | ||||||||||||
Employer contribution to bonus shares | (244 | ) | 154 | — | 170 | |||||||||||
Share-based payments | 1,814 | 1,078 | 3,446 | 2,441 | ||||||||||||
Total | 7,079 | 6,208 | 14,351 | 12,123 | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||||||
Non-employee warrants | 251,693 | 256,693 | 251,693 | 256,693 | ||||||||||||
Stock options | 5,290,569 | 3,442,358 | 5,290,569 | 3,442,358 | ||||||||||||
Restricted stock units | 1,509,078 | 1,145,223 | 1,509,078 | 1,145,223 | ||||||||||||
Prefunded warrants | 28,276,331 | 28,276,331 | 28,276,331 | 28,276,331 |
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Non-employee warrants | 256,693 | 256,693 | 256,693 | 256,693 | ||||||||||||
Stock options | 3,442,358 | 2,594,410 | 3,442,358 | 2,594,410 | ||||||||||||
Restricted stock units | 1,145,223 | 1,092,445 | 1,145,223 | 1,092,445 | ||||||||||||
Prefunded warrants | 28,276,331 | — | 28,276,331 | — |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2021,2022, included in our Annual Report on Form2021,2022, filed with the Securities and Exchange Commission on March 9, 2022,2, 2023, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.
Overview
We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT
Our most advanced clinical program is Viaskin Peanut.
On March 7, 2023, the Company announced that in Part A, patients in both treatment arms showed consistent treatment effects after 12 months of therapy, as assessed by a double-blind placebo-controlled food challenge and biomarker results. Part A subjects were not included in Part B and the efficacy analyses from Part A were not statistically powered to demonstrate superiority of either dose versus placebo. These results validate the ongoing investigationscreening of the 250 Pg dosefirst patient in this age group, which is the dose being studied in Part BVITESSE. Screening of the study. Enrollment for Part B of EPITOPE was completedlast patient is anticipated in the first quarter of 2022.
On April 19, 2023, the treatment responder criteria after 12 months, as compared to 33.5% of subjects inCompany outlined the placebo arm (difference in response rates = 33;4 %, 95 % CI = 22.4% - 44.5 %).
On May 10, 2023, the New England Journal of Medicine (NEJM) published results that demonstrated epicutaneous immunotherapy (EPIT) with VP was statistically superior to placebo in desensitizing children to peanut exposure by increasing the peanut dose that triggers allergic symptoms. As stated in an accompanying editorial piece, these data are seen as “very good news” for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years. Following this publication, the Company confirmed it is advancing regulatory efforts for VP in toddlers ages 1 to 31-3 years given the high unmet need and absence of approved treatments for this vulnerable population.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Condensed Consolidated Financial Statements in Part I, Item 1 of our Annual Report.
17
Business trends and Results of Operations
Comparison of the Three Months Ended June 30, 20222023 and 2021
The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the three months ended June 30, 20222023 and 2021.
Three months ended June 30, | ||||||||||||||||
2022 | 2021 | $ change | % change | |||||||||||||
Operating income | $ | 1,529 | $ | (1,488 | ) | 3,016 | (203 | )% | ||||||||
Operating expenses | ||||||||||||||||
Research and development expenses | (18,611 | ) | (20,179 | ) | 1,568 | (8 | )% | |||||||||
Sales and marketing expenses | (1,037 | ) | (1,198 | ) | 162 | (13 | )% | |||||||||
General and administrative expenses | (5,704 | ) | (8,269 | ) | 2,564 | (31 | )% | |||||||||
Total Operating expenses | (25,352 | ) | (29,646 | ) | 4,309 | (15 | )% | |||||||||
Financial income | 784 | 46 | 737 | * | ||||||||||||
Income tax | — | 434 | (434 | ) | (100 | )% | ||||||||||
Net loss | $ | (23,039 | ) | $ | (30,654 | ) | 7,629 | (25 | )% | |||||||
Basic/diluted Net loss per share attributable to shareholders | $ | (0.35 | ) | $ | (0.56 | ) |
Three months ended June 30, | ||||||||||||||||
2023 | 2022 | $ change | % change | |||||||||||||
Operating income | $ | 2,288 | $ | 1,529 | 759 | 50 | % | |||||||||
Operating expenses | ||||||||||||||||
Research and development expenses | (17,616 | ) | (18,611 | ) | 995 | (5 | )% | |||||||||
Sales and marketing expenses | (516 | ) | (1,037 | ) | 520 | (50 | )% | |||||||||
General and administrative expenses | (9,231 | ) | (5,704 | ) | (3,527 | ) | 62 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Total Operating expenses | (27,364 | ) | (25,352 | ) | (2,012 | ) | 8 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Financial income (expenses) | 846 | 784 | 62 | 8 | % | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Income tax | (13 | ) | — | (13 | ) | — | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Net loss | $ | (24,243 | ) | $ | (23,039 | ) | (1,204 | ) | 5 | % | ||||||
|
|
|
|
|
|
|
| |||||||||
Basic/diluted Net loss per share attributable to shareholders | $ | (0.26 | ) | $ | (0.35 | ) |
Operating Income
The following table summarizes our operating income during the three months ended June 30, 20222023 and 2021:
Three months ended June 30, | ||||||||||||||||
2022 | 2021 | $ change | % change | |||||||||||||
Sales | — | — | — | — | ||||||||||||
Other income | 1,529 | (1,488 | ) | 3,016 | (203 | )% | ||||||||||
Research tax credit | 1,491 | 1,870 | (379 | ) | (20 | )% | ||||||||||
Other operating income | 37 | (3,358 | ) | 3,396 | (101 | )% | ||||||||||
Total operating income | 1,529 | (1,488 | ) | 3,016 | (203 | )% | ||||||||||
Three months ended June 30, | ||||||||||||||||
2023 | 2022 | $ change | % change | |||||||||||||
Sales | — | — | — | — | ||||||||||||
Other income | 2,288 | 1,529 | 759 | 50 | % | |||||||||||
Research tax credit | 1,975 | 1,491 | 484 | 32 | % | |||||||||||
Other operating income | 312 | 37 | 275 | 734 | % | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Total operating income | 2,288 | 1,529 | 759 | 50 | % | |||||||||||
|
|
|
|
|
|
|
|
Our operating income is primarily generated from the French research tax credit (
The increase in operating income was primarily due to $(1.5)the increase by $0.5 million duringin French research tax credit as the eligible employee-related costs increased to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.
In addition, other operating income increased by $0.3 million for the three months ended June 30, 2021. The increase in operating income is primarily attributable2023, compared to the revenue recognized under the Nestlé’s collaboration agreement, asthree months ended June 30, 2022, after we updated the measurement of progress of the Phase II2 clinical trial conducted as part of the agreement. During the three months ended June 30, 2021 negative revenue was recognized under the Nestlé’s collaboration agreement due to delays in new patient enrollment.The decrease in research tax credit is attributable to the decline of eligible expenses in connection with Research and Development costs.
Operating Expenses
Research and Development Expenses
The following table summarizes our research and development expenses incurred during the three months ended June 30, 20222023 and 2021:2022:
18
Three Months Ended June 30, | ||||||||||||||||
Research and Development expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External clinical-related expenses | 11,664 | 9,808 | 1,856 | 19 | % | |||||||||||
Employee-related costs | 2,622 | 3,206 | (584 | ) | (18 | )% | ||||||||||
Share-based payment expenses | 475 | 187 | 289 | 155 | % | |||||||||||
Depreciation, amortization and other costs | 3,850 | 6,978 | (3,128 | ) | (45 | )% | ||||||||||
Total Research and Development expenses | 18,611 | 20,179 | (1,568 | ) | (8 | )% | ||||||||||
Three Months Ended June 30, | ||||||||||||||||
Research and Development expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External clinical-related expenses | 11,421 | 11,664 | (243 | ) | (2 | )% | ||||||||||
Employee-related costs (excl. share-based payments) | 3,278 | 2,622 | 656 | 25 | % | |||||||||||
Share-based payment expenses | 736 | 475 | 261 | 55 | % | |||||||||||
Depreciation, amortization and other costs | 2,181 | 3,850 | (1,669 | ) | (43 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total Research and Development expenses | 17,616 | 18,611 | (995 | ) | 50 | % | ||||||||||
|
|
|
|
|
|
|
|
Research and Development expenses decreased by $1.6$1.0 million for the three months ended June 30, 2022,2023, compared to the three months ended June 30, 2021,2022, primarily due to an increase in external clinical-related expenses following the launchreversal of work$1.1 million of the loss at completion recorded as other costs on VITESSE protocol. We have also continued to practice financial discipline and implemented further cost containment strategies.
In addition external clinical expenses decreased by $0.2 million as a result of differences in phasing of on-going clinical trials between the new organization.
Decreases in depreciation, amortization and other costs was primarily due toimpacts of the loss at completion recorded onand in external clinical-related expenses were partially offset by the Phase II clinicalincrease by $0.7 million in employee-related costs (excl. share-based payments) to support research and development activities (1) after the initiation of the VITESSE trial conductedwith the first patient screened in March 2023, and (2) as part of the Nestlé agreement.
Sales and Marketing expenses
The following table summarizes our sales and marketing expenses incurred during the three months ended June 30, 20222023 and 2021:
Three Months Ended June 30, | ||||||||||||||||
Sales and Marketing expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External professional services | 399 | 307 | 92 | 30 | % | |||||||||||
Employee-related costs | 289 | 430 | (140 | ) | (33 | )% | ||||||||||
Share-based payment expenses | 55 | 89 | (34 | ) | (38 | )% | ||||||||||
Depreciation, amortization and other costs | 294 | 373 | (79 | ) | (21 | )% | ||||||||||
Total Sales and Marketing expenses | 1,037 | 1,198 | (162 | ) | (13 | )% | ||||||||||
Three Months Ended June 30, | ||||||||||||||||
Sales and Marketing expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External professional services | 80 | 399 | (319 | ) | (80 | )% | ||||||||||
Employee-related costs (excl. share-based payments) | 173 | 289 | (116 | ) | (40 | )% | ||||||||||
Share-based payment expenses | 35 | 55 | (20 | ) | (36 | )% | ||||||||||
Depreciation, amortization and other costs | 229 | 294 | (65 | ) | (22 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total Sales and Marketing expenses | 516 | 1,037 | (520 | ) | (50 | )% | ||||||||||
|
|
|
|
|
|
|
|
Sales and marketing expenses amounted to $1decreased by $0.5 million for the three months ended June 30, 2022, compared to $1.2 million for the three months ended June 30, 2021.
General and Administrative expenses
The following table summarizes our general and administrative expenses incurred during the three months ended June 30, 20222023 and 2021:
Three Months Ended June 30, | ||||||||||||||||
General and Administrative expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External professional services | 1,771 | 1,922 | (151 | ) | (8 | )% | ||||||||||
Employee-related costs | 2,220 | 2,180 | 40 | 2 | % | |||||||||||
Share-based payment expenses | 548 | 819 | (271 | ) | (33 | )% | ||||||||||
Depreciation, amortization and other costs | 1,166 | 3,348 | (2,182 | ) | (65 | )% | ||||||||||
Total General and Administrative expenses | 5,704 | 8,269 | (2,564 | ) | (31 | )% | ||||||||||
Three Months Ended June 30, | ||||||||||||||||
General and Administrative expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External professional services | 3,806 | 1,771 | 2,034 | 115 | % | |||||||||||
Employee-related costs (excl. share-based payments) | 1,814 | 2,220 | (405 | ) | (18 | )% | ||||||||||
Share-based payment expenses | 1,043 | 548 | 496 | 91 | % | |||||||||||
Depreciation, amortization and other costs | 2,568 | 1,166 | 1,402 | 120 | % | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Total General and Administrative expenses | 9,231 | 5,704 | 3,527 | 62 | % | |||||||||||
|
|
|
|
|
|
|
|
General and Administrative expenses decreasedincreased by $2.6$3.5 million for the three months ended June 30, 2022,2023, compared to the three months ended June 30, 2021 primarily2022, mainly due to one-time costs associated with financing activities, organizational planning, market research and planning activities. In addition, we recorded a decrease in depreciation, amortization and otherprovision amounting to $0.7 million as of June 30, 2023, as our best estimate of costs as we continued to practice financial discipline and implemented further cost containment strategies.be incurred if the Montrouge office lease agreement is not renewed at its July 2024 terms.
19
Financial income (expense)
Our financial income was approximately $784,000$0.8 million for the three months ended June 30, 2022,2023, compared to a financial income of $46,000$0.8 million for the three months ended June 30, 2021.2022. This item mainly includes foreign exchangethe financial income and expenses.
Income tax
Our income tax profitexpense was nil for the three months ended June 30, 2022, compared to $0.12023 and June 30, 2022.
Net loss
Net loss was $24.2 million for the three months ended June 30, 2021. This profit mainly resulted from U.S. tax refunds.
Comparison of the Six Months Ended June 30, 20222023 and 2021
The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. Dollars, for the six months ended June 30, 20222023 and 2021.
Six months ended June 30, | ||||||||||||||||
2022 | 2021 | $ change | % change | |||||||||||||
Operating income | $ | 4,074 | $ | 1,453 | 2,621 | 180 | % | |||||||||
Operating expenses | ||||||||||||||||
Research and development expenses | (30,834 | ) | (42,343 | ) | 11,509 | (27 | )% | |||||||||
Sales and marketing expenses | (1,500 | ) | (1,927 | ) | 427 | (22 | )% | |||||||||
General and administrative expenses | (12,334 | ) | (17,951 | ) | 5,617 | (31 | )% | |||||||||
Total Operating expenses | (44,669 | ) | (62,221 | ) | 17,552 | (28 | )% | |||||||||
Financial income (expense) | 936 | 261 | 675 | 258 | % | |||||||||||
Income tax | (87 | ) | 404 | (491 | ) | (122 | )% | |||||||||
Net loss | $ | (39,746 | ) | $ | (60,103 | ) | 20,357 | (34 | )% | |||||||
Basic/diluted Net loss per share attributable to shareholders | $ | (0.66 | ) | $ | (1.09 | ) | ||||||||||
Six months ended June 30, | ||||||||||||||||
2023 | 2022 | $ change | % change | |||||||||||||
Operating income | $ | 4,482 | $ | 4,074 | 407 | 10 | % | |||||||||
Operating expenses | ||||||||||||||||
Research and development expenses | (33,653 | ) | (30,834 | ) | (2,819 | ) | 9 | % | ||||||||
Sales and marketing expenses | (950 | ) | (1,500 | ) | 551 | (37 | )% | |||||||||
General and administrative expenses | (16,120 | ) | (12,334 | ) | (3,786 | ) | 31 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Total Operating expenses | (50,723 | ) | (44,669 | ) | (6,054 | ) | 14 | % | ||||||||
|
|
|
|
|
|
|
| |||||||||
Financial income (expense) | 1,450 | 936 | 515 | 55 | % | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Income tax | (13 | ) | (87 | ) | 74 | (85 | )% | |||||||||
|
|
|
|
|
|
|
| |||||||||
Net loss | $ | (44,804 | ) | $ | (39,746 | ) | (5,058 | ) | 13 | % | ||||||
|
|
|
|
|
|
|
| |||||||||
Basic/diluted Net loss per share attributable to shareholders | $ | (0.48 | ) | $ | (0.66 | ) | ||||||||||
|
|
|
|
|
|
|
|
Operating Income
The following table summarizes our operating income during the six months ended June 30, 20222023 and 2021:
Six months ended June 30, | ||||||||||||||||
2022 | 2021 | $ change | % change | |||||||||||||
Sales | — | — | ||||||||||||||
Other income | 4,074 | 1,453 | 2,621 | 180 | % | |||||||||||
Research tax credit | 3,060 | 3,677 | (617 | ) | (17 | )% | ||||||||||
Other operating income | 1,014 | (2,225 | ) | 3,238 | (146 | )% | ||||||||||
Total operating income | 4,074 | 1,453 | 2,621 | 180 | % | |||||||||||
Six months ended June 30, | ||||||||||||||||
2023 | 2022 | $ change | % change | |||||||||||||
Sales | — | — | ||||||||||||||
Other income | 4,482 | 4,074 | 407 | 10 | % | |||||||||||
Research tax credit | 3,741 | 3,060 | 680 | 22 | % | |||||||||||
Other operating income | 741 | 1,014 | (273 | ) | (27 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total operating income | 4,482 | 4,074 | 407 | 10 | % | |||||||||||
|
|
|
|
|
|
|
|
Our operating income was primarily generated fromconsisted of the French research tax credit (
The increase in operating income was due to $1.5the increase by $0.7 million duringin the French research tax credit as both eligible employee-related costs and eligible external clinical-related expenses increased to support research and development activities (1) after the initiation of the VITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.
20
The increase in research tax credit was partially offset by the decrease by $0.3 million in other operating income for the six months ended June 30, 2021.
Operating Expenses
Research and Development Expenses
The following table summarizes our research and developmentR&D expenses incurred during the six months ended June 30, 20222023 and 2021:
Six Months Ended June 30, | ||||||||||||||||
Research and Development expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External clinical-related expenses | 19,014 | 22,686 | (3,672 | ) | (16 | )% | ||||||||||
Employee-related costs | 5,114 | 7,297 | (2,183 | ) | (30 | )% | ||||||||||
Share-based payment expenses | 1,058 | 814 | 244 | 30 | % | |||||||||||
Depreciation, amortization and other costs | 5,648 | 11,546 | (5,898 | ) | (51 | )% | ||||||||||
Total Research and Development expenses | 30,834 | 42,343 | (11,509 | ) | (27 | )% | ||||||||||
Six Months Ended June 30, | ||||||||||||||||
Research and Development expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External clinical-related expenses | 21,892 | 19,014 | 2,878 | 15 | % | |||||||||||
Employee-related costs (excl. share-based payments) | 6,598 | 5,114 | 1,484 | 29 | % | |||||||||||
Share-based payment expenses | 1,423 | 1,058 | 365 | 34 | % | |||||||||||
Depreciation, amortization and other costs | 3,741 | 5,648 | (1,908 | ) | (34 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total Research and Development expenses | 33,653 | 30,834 | 2,819 | 9 | % | |||||||||||
|
|
|
|
|
|
|
|
Research and Development expenses decreasedincreased by $11.5$2.8 million for the six months ended June 30, 20222023, compared to the six months ended June 30, 20212022, primarily due to a decreasethe increase by $2.9 million and by $1.5 million in external clinical-related expenses as main componentand in employee-related costs (excl. share-based payments) respectively, to support research and development activities (1) after the initiation of the workVITESSE trial with the first patient screened in March 2023, and (2) as part of the new safety study for toddlers after the FDA confirmed additional safety data is required for BLA.
Increases in both external clinical-related expenses and employee-related costs were partially offset by the reversal of $1.1 million of the loss at completion recorded as other costs on the Phase 2 clinical studies suchtrial conducted as REALISE and EPITOPE has been finalized duringpart of the year 2021. We have also continued to practice financial discipline and implemented further cost containment strategies.
Sales and Marketing expenses
The following table summarizes our sales and marketing expenses incurred during the six months ended June 30, 20222023 and 2021:
Six Months Ended June 30, | ||||||||||||||||
Sales and Marketing expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External professional services | 521 | 391 | 130 | 33 | % | |||||||||||
Employee-related costs | 539 | 877 | (338 | ) | (39 | )% | ||||||||||
Share-based payment expenses | 49 | 159 | (110 | ) | (69 | )% | ||||||||||
Depreciation, amortization and other costs | 391 | 500 | (109 | ) | (22 | )% | ||||||||||
Total Sales and Marketing expenses | 1,500 | 1,927 | (427 | ) | (22 | )% | ||||||||||
Six Months Ended June 30, | ||||||||||||||||
Sales and Marketing expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External professional services | 348 | 521 | (173 | ) | (33 | )% | ||||||||||
Employee-related costs (excl. share-based payments) | 303 | 539 | (237 | ) | (44 | )% | ||||||||||
Share-based payment expenses | 70 | 49 | 21 | 41 | % | |||||||||||
Depreciation, amortization and other costs | 229 | 391 | (162 | ) | (41 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Total Sales and Marketing expenses | 950 | 1,500 | (551 | ) | (37 | )% | ||||||||||
|
|
|
|
|
|
|
|
Sales and marketing expenses decreased by $0.4$ 0.6 million for the six months ended June 30, 2022,2023, compared to the six months ended June 30, 2021,2022, primarily due to a decrease inof external professional services and employee-related costs.
General and Administrative expenses
The following table summarizes our general and administrative expenses incurred during the six months ended June 30, 20222023 and 2021:2022:
Six Months Ended June 30, | ||||||||||||||||
General and Administrative expenses | 2023 | 2022 | $ change | % change | ||||||||||||
External professional services | 5,512 | 2,879 | 2,633 | 91 | % | |||||||||||
Employee-related costs (excl. share-based payments) | 4,005 | 4,029 | (25 | ) | (1 | )% | ||||||||||
Share-based payment expenses | 1,954 | 1,333 | 620 | 47 | % | |||||||||||
Depreciation, amortization and other costs | 4,650 | 4,093 | 557 | 14 | % | |||||||||||
|
|
|
|
|
|
|
| |||||||||
Total General and Administrative expenses | 16,120 | 12,334 | 3,786 | 31 | % | |||||||||||
|
|
|
|
|
|
|
|
21
Six Months Ended June 30, | ||||||||||||||||
General and Administrative expenses | 2022 | 2021 | $ change | % change | ||||||||||||
External professional services | 2,879 | 4,210 | (1,330 | ) | (32 | )% | ||||||||||
Employee-related costs | 4,029 | 5,211 | (1,181 | ) | (23 | )% | ||||||||||
Share-based payment expenses | 1,333 | 1,554 | (221 | ) | (14 | )% | ||||||||||
Depreciation, amortization and other costs | 4,093 | 6,977 | (2,884 | ) | (41 | )% | ||||||||||
Total General and Administrative expenses | 12,334 | 17,951 | (5,617 | ) | (31 | )% | ||||||||||
General and Administrative expenses decreasedincreased by $5.7$3.8 million for the six months ended June 30, 2022,2023, compared to the six months ended June 30, 2021, primarily2022, mainly due to one-time costs associated with financing activities, organizational planning, market research and planning activities. In addition, we recorded a decreaseprovision amounting to $0.7 million as of depreciation, amortization and other costs.
Financial income (expense)
Our financial income was $1.5 million for the six months ended June 30, 2023, compared to a financial income of $0.9 million for the six months ended June 30, 2022, compared to a2022. This item mainly includes financial income of $0.3on our financial assets.
Income tax
Our income tax expense was nil for the six months ended June 30, 2023 and June 30, 2022.
Net loss
Net loss was $ 44.8 million for the six months ended June 30, 2021. This item mainly includes foreign exchange income (expense).
Liquidity and Capital Resources
Financial Condition
On June 30, 2022,2023, we had $248$174 million in cash and cash equivalents compared to $77.3$209.2 million of cash and cash equivalents on December 31, 2021.2022. We have incurred operating losses and negative cash flows from operations since our inception. Net cash used for operating activities was $12.3$ 46.4 million and $66.5$11.7 million for the six months ended June 30, 20222023 and 2021,2022, respectively. As of June 30, 2022,2023, we recorded a net loss of $23 million.Our$ 44.8 million. Our net cash flows provided by financing activities increaseddecreased to $7.8 million during the six months ended June 30, 2023 from $195.2 million during the six months ended June 30, 2022 from $1.1 million duringdue to more important financing operations in first semester of 2022 (May 2022 ATM and June 2022 PIPE) compared to 2023 (June 2023 ATM).
Our condensed consolidated financial statements have been prepared on a going concern basis assuming that based on our current operations, as well as our plans and assumptions, we expect that our balance of cash and cash equivalents at closing date will be sufficient to fund our operations for at least the six months ended June 30, 2021. Financing activities consisted mainlynext 12 months. As such, no adjustments have been made to the condensed consolidated financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should we not be able to continue as a going concern.
Sources of Liquidity and Material Cash Requirements
We have incurred net losses each year since our inception. Substantially all of our underwritten global offeringnet losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. We have not incurred any bank debt.
Payments associated with Research tax credits (Crédit d’Impôt Recherche) contribute to fund our short-term cash requirements. We intend to seek additional capital as we prepare for the second quarterlaunch of 2022.
In May 2022, we established an At-The-Market (“ATM”) program to offer and sell, including with unsolicited investors who have expressed an interest, a total gross amount of up to $100 million of American Depositary Shares (“ADSs”), each ADS representing one-half of one ordinary share of the Company. The ATM program is intended to be effective through the expiration of the Company’s existing registration statement registering the ADSs to be issued under the ATM program, i.e. until July 16, 2024, unless terminated prior to such date in accordance with the sales agreement or the maximum amount of the program has been reached. The Company’s intent is to use the net proceeds, if any, of sales of ADSs issued under the program, together with its existing cash and cash equivalents, primarily for activities associated with potential approval and launch of Viaskin Peanut, as well as to advance the development of the Company’s product candidates using its Viaskin Peanut platform and for working capital and other general corporate purposes.
Pursuant to the ATM program, the Company issued and completed sales of new Ordinary Shares in the form of ADSs for a total gross amount of $15.3 million on May 4, 2022, and of $7.8 million on June 14, 2023. Respectively, 6,036,238 and 2,052,450 new Ordinary Shares in the form of ADSs were issued through a capital increase without preferential subscription rights of the shareholders reserved to specific categories of persons fulfilling certain characteristics (the “ATM issuance”), at a unit subscription price of $1.27 and $1.90 per ADS, each ADS giving the right to receive one-half of one ordinary share of the Company.
22
We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to us, including reduced ability to raise additional capital when needed or on acceptable terms, if at all.
Material Cash Requirements Due by the period Ended June 30, | ||||||||||||||||||||
2023 | 2024 | 2025 | Thereafter | Total | ||||||||||||||||
(Amounts in thousands) | ||||||||||||||||||||
Conditional advances | 156 | — | — | — | 156 | |||||||||||||||
Operating leases | 2,154 | 1,862 | 295 | — | 4,312 | |||||||||||||||
Purchase obligations - Obligations Under the Terms of CRO Agreements | 17,057 | 6,721 | 4,969 | — | 30,586 | |||||||||||||||
Total | 19,367 | 8,583 | 5,264 | — | 35,054 |
Operating leases
Our corporate headquarters are located in Montrouge, France. Our principal offices occupy a 4,470 square meter facility, pursuant to a lease agreement dated March 3, 2015, and represents a $3.5$0.8 million cash requirement as of June 30, 20222023 which expires July 31, 2024.
Our primary U.S. office is located in Basking Ridge, New Jersey. In March 8, 2024.
There have been no material changes in our operating leases from those disclosed in the Annual Report.
Purchase obligations - Obligations Under the Terms of CRO Agreements
In connection with the launch of our clinical trials for Viaskin Peanut and Viaskin Milk, we signed agreements with several contract research organizations. Expenses associated with
There have been no material changes in our purchase obligations from those disclosed in the ongoing trials amounted globally to $105.5 million. As of June 30, 2022, the amount we are still obligated to pay in connection with these contracts through 2024 is $30.6 million.
Summary Statement of Cash Flows
The table below summarizes our sources and uses of cash for the six months ended June 30, 20222023 and 2021.
Six months ended June 30, | ||||||||||||||||
(Amounts in thousands of U.S. Dollars) | 2022 | 2021 | $ change | % of change | ||||||||||||
Net cash flow used in operating activities | (11,733 | ) | (66,503 | ) | 54,770 | (82 | )% | |||||||||
Net cash flow used in investing activities | (218 | ) | (13 | ) | (206 | ) | 1595 | % | ||||||||
Net cash flow provided by financing activities | 195,222 | 1,071 | 194,151 | * | ||||||||||||
Effect of exchange rate changes on cash and cash equivalents | (12,600 | ) | (5,423 | ) | (7,177 | ) | 132 | % | ||||||||
Net (decrease) increase in cash and cash equivalents | 170,670 | (70,868 | ) | 241,538 | (341 | )% | ||||||||||
Six months ended June 30, | ||||||||||||||||
(Amounts in thousands of U.S. Dollars) | 2023 | 2022 | $ change | % of change | ||||||||||||
Net cash flow used in operating activities | (46,394 | ) | (11,733 | ) | (34,661 | ) | 295 | % | ||||||||
Net cash flow used in investing activities | (299 | ) | (218 | ) | (80 | ) | 37 | % | ||||||||
Net cash flow provided by financing activities | 7,793 | 195,222 | (187,429 | ) | (96 | )% | ||||||||||
Effect of exchange rate changes on cash and cash equivalents | 3,668 | (12,600 | ) | 16,268 | (129 | )% | ||||||||||
|
|
|
|
|
|
|
| |||||||||
Net (decrease) increase in cash and cash equivalents | (35,232 | ) | 170,670 | (205,903 | ) | (121 | )% | |||||||||
|
|
|
|
|
|
|
|
Operating Activities
Our net cash flows used in operating activities were $11.7$46.4 million and $66.5$11.7 million during the six months ended June 30, 20222023 and 2021,2022, respectively. Our net cash flows used in operating activities increased by $54.8$ 34.7 million, or 82%, mainly due to cost containment measures and to the workforce reduction following full implementationrepayment in 2022 of the new organization
Investing Activities
Our net cash flows used in investing activities was approximately $218,000were $0.3 million and $13,000$0.2 million during the six months ended June 30, 2023 and 2022, and 2021, respectively.
Financing Activities
Our net cash flows provided by financing activities increasedwas $ 7.8 million during the six months ended June 30, 2023 that consisted of the ATM in June 2023 compared to $195.2 million during the six months ended June 30, 2022, from $1.1 million duringthat consisted of the six months endedMay 2022 ATM and the June 30, 2021. Financing activities consisted mainly of our underwritten global offering in the second quarter of 2022.2022 PIPE.
23
Off-Balance
We have not entered into any
Smaller Reporting Company Status
We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not changed materially from those disclosed inrequired to provide the Annual Report.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Based on its evaluation as of June 30, 2022,2023, our management, including our Chief Executive Officer and Chief Financial Officer,
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules
Limitation on Effectiveness of Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and
PART II – Other information
Item 1. Legal Proceedings
See “Note 2: Significant Events and Transactions – Legal Proceedings” in the notes to the condensed consolidated financial statements included elsewhere in this Report.
24
Item 1A. Risk Factors
Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and trading price of our securities. In addition to the other information set forth below, therein this Quarterly Report, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report. There have been no material changes in our risk factors from those disclosed in the Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the six months ended June 30, 2022,2023, we issued the following unregistered securities:
On March 23, 2023, the issuance of |
• | On May 19, 2023, the |
• | On May 22, 2023, the issuance of an aggregate of 14,364 ordinary shares to non-U.S. employees upon settlement of RSUs; and |
• | On May 24, 2023, the issuance of an aggregate of 34,321 ordinary shares to U.S. and non-U.S. employees upon settlement of RSUs. |
None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe these transactions were exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act or Regulation S promulgated under Section 5 of the Securities Act, as transactions by an issuer not involving any public offering or as offerings made to
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
Item 6. Exhibits.
Exhibit Index
Exhibit | Description | Incorporated by Reference | ||||||||||||||||
Schedule/ Form | File Number | Exhibit | File Date | |||||||||||||||
3.1 | By-laws (statuts) of the registrant (English translation) | 10-Q | 001-36697 | 3.1 | 5/04/23 | |||||||||||||
31.1 | Certificate of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as Amended | |||||||||||||||||
31.2 | Certificate of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended | |||||||||||||||||
32.1* | Certificate of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002, as amended | |||||||||||||||||
101.INS | XBRL Instance Document | |||||||||||||||||
101.SCH | XBRL Taxonomy Extension Schema Document | |||||||||||||||||
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
25
Exhibit | Description | Incorporated by Reference | ||||||||||||||||
Schedule/ Form | File Number | Exhibit | File Date | |||||||||||||||
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |||||||||||||||||
101.LAB | XBRL Taxonomy Extension Labels Linkbase Document | |||||||||||||||||
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |||||||||||||||||
104 | Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101. |
* | Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Exchange Act, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DBV Technologies S.A. | ||||||
(Registrant) | ||||||
Date: | By: | /s/ Daniel Tassé | ||||
Daniel Tassé | ||||||
Chief Executive Officer | ||||||
(Principal Executive Officer) | ||||||
Date: | By: | /s/ Sébastien Robitaille | ||||
Sébastien Robitaille | ||||||
Chief Financial Officer | ||||||
(Principal Financial and Accounting Officer) |
26